Enzene Biosciences pertuzumab
Pertuzumab biosimilar developed by Enzene Biosciences (Alkem). Reference product Perjeta.
About Enzene Biosciences pertuzumab
Enzene received its pertuzumab permission in India in June 2025, the third Indian company to make it, adding to its adalimumab, bevacizumab, denosumab and ranibizumab.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Enzene Biosciences pertuzumab holds an approval, these are the other pertuzumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 2 | Intas Pharmaceuticals (Intas pertuzumab), Zydus Lifesciences (Zydus pertuzumab) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Enzene Biosciences: Enzene Biosciences adalimumab, Enzene Biosciences bevacizumab, Enzene Biosciences ranibizumab, Enzene Biosciences teriparatide, Osqay / Enzene denosumab.
Chronology
- CDSCOJun 2025CDSCO permission granted
Sources
Planning pertuzumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant